
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
Published on March 7, 2024
This report describes effectiveness of nirsevimab against respiratory syncytial virus-associated hospitalizations in infants.
